Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2013 Oct;5(10):1039-42.
doi: 10.2217/imt.13.96.

Vaccination With Dendritic Cell-Tumor Fusion Cells in Multiple Myeloma Patients: A Promising Strategy?

Affiliations
Comment

Vaccination With Dendritic Cell-Tumor Fusion Cells in Multiple Myeloma Patients: A Promising Strategy?

Maria A Garcia-Marquez et al. Immunotherapy. .

Abstract

Evaluation of: Rosenblatt J, Avivi I, Vasir B et al. Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. Clin. Cancer Res. 19(13), 3640-3648 (2013). Recently, dendritic cell (DC)-tumor fusion vaccines have been explored as a promising therapeutic approach for the treatment of cancer. Fusion vaccines offer several advantages that distinguish them from other DC-based vaccines. In this Phase II clinical trial, Rosenblatt et al. demonstrate that repeated immunization with a DC-tumor fusion vaccine after autologous stem cell transplantation induces myeloma-specific immunity and improves clinical response. They showed that generation of an autologous fusion vaccine with dendritic and myeloma cells was feasible and that vaccination was well tolerated without grade 3-4 toxicities. The results of this study suggest that the time after autologous stem cell transplantation represents a unique setting for cancer vaccination and that combining autologous stem cell transplantation with post-transplant vaccination increases the immunogenicity.

Comment on

Similar articles

See all similar articles

Cited by 1 article

Substances

Feedback